Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes.A Belgian Precision 2 study

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Belgian Society Of Medical Oncology

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Pathological Conditions, Signs and Symptoms [C23]

Trial duration

7 Feb 2019 → 31 Oct 2025

Decision date (initial)

2024-10-18

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

External identifiers

EU CT number

2024-518522-32-00

EudraCT number

2018-002966-37

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Therapy

document anti-tumor activity (measured by response rate and
response duration) of olaparib in advanced cancer patients that have a
germline mutation or a somatic tumor mutation among a defined list of HR
genes: BRCA1/2, ATM, BARD1, BRIP1, CHEK1, CHEK2, MRE11A,
NBN, PALB2, RAD50, RAD 51B, RAD51C, RAD51D, RAD54L,
FAM175A, CDK12, FANCL, p53 (only germline) and PPP2R2A. This is
the minimal list of genes when mutated causing an HRD currently included
in the routine genetic panel testing in the Belgian genetics labs. Other gene
mutations proven to cause HRD are also eligible pending approval by the
PI.

Secondary objectives 1

1. correlate efficacy with locus-specific LOH in the tumors in case of cancers not routinely associated with the germline mutations (optional and separate informed consents for participants). Although the presence of LOH is not an absolute marker of the relevance of the mutation in a particular cancer, it gives a strong probability against which the response data can be evaluated.

Conditions and MedDRA coding

Basket tumors

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 12

1. Provision of informed consent prior to any study specific procedures
2. Female or male aged > 18 years
3. Histologically proven advanced cancer, either locally or metastatic, harboring a specific pathogenic genetic alteration (with the exception of breast, or prostate cancer patients harboring a BRCA1/2 mutation and HRD ovarian cancer)
4. No approved targeted therapy for the specific genetic alteration in the specific tumor type
5. No other genomic driven phase I, II or III trial available for the specific genomic alteration in the specific tumor type
6. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
7. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
8. Patients must have a life expectancy ≥16 weeks
9. Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.
10. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
11. At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT and is suitable for repeated assessment.
12. Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary cancer must be available for local genetic testing.

Exclusion criteria 23

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
2. Ovarian cancer patients harboring a HRD and breast and prostate cancer patients who carry a BRCA1/2 mutation
3. Previous enrolment in the present study
4. Participation in another clinical study with an investigational product during the last 4 weeks or radiotherapy (except for palliative reasons) within three weeks prior to study treatment.
5. History of non-compliance to medical regimens
6. Any previous treatment with PARP inhibitor, including olaparib.
7. Other malignancy within the last 5 years except: adequately treated nonmelanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥5 years. Patients with a history of localized triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
8. Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or indicating uncontrolled, potentially reversible cardiac conditions as judged by the investigator (er., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation >500ms, electrolyte disturbances, etc.) or patients with congenital long QT syndrome
9. Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within four weeks prior to study treatment. Patients must have recovered from radiotherapy toxicities prior to enrollment.
10. Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
11. Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
12. Persistent toxicities (Common Terminology Criteria for Adverse Event (CTCAE) > grade 2) caused by previous cancer therapy, excluding alopecia.
13. Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
14. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
15. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
16. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent.
17. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
18. Breast feeding women.
19. Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
20. Patients with a known hypersensitivity to olaparib or any of the excipients of the product.
21. Patients with known active hepatitis (i.e. Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
22. Previous allogenic bone marrow transplant or single/double umbilical cord blood transplantation (dUCBT)
23. Whole blood transfusions in the last 120 days prior to entry to the study (packed red blood cells and platelet transfusions are acceptable, for timing refer to inclusion criteria no.3)

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. Response rate according to RECIST 1.1
2. Response duration

Secondary endpoints 4

1. Correlate efficacy with locus-specific LOH in the tumors in case of cancers atypical for the germline mutations.
2. PFS
3. OS
4. Safety by reporting all adverse events

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Belgian Society Of Medical Oncology

Sponsor organisation

Belgian Society Of Medical Oncology

Address

Nijverheidsstraat 24

City

Brussels

Postcode

1040

Country

Belgium

Scientific contact point

Organisation

Belgian Society Of Medical Oncology

Contact name

Mieke

Public contact point

Organisation

Belgian Society Of Medical Oncology

Contact name

Mieke

Locations

1 EU/EEA country · 1 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 7 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications